South Korea · Delayed Price · Currency is KRW Kukje Pharma Statistics
Total Valuation
Kukje Pharma has a market cap or net worth of KRW 96.93 billion. The enterprise value is 116.62 billion.
| Market Cap | 96.93B |
| Enterprise Value | 116.62B |
Important Dates
The last earnings date was Thursday, April 2, 2026.
| Earnings Date | Apr 2, 2026 |
| Ex-Dividend Date | Mar 12, 2026 |
Share Statistics
Kukje Pharma has 20.36 million shares outstanding. The number of shares has increased by 0.08% in one year.
| Current Share Class | 20.36M |
| Shares Outstanding | 20.36M |
| Shares Change (YoY) | +0.08% |
| Shares Change (QoQ) | -0.27% |
| Owned by Insiders (%) | 12.69% |
| Owned by Institutions (%) | 6.21% |
| Float | 12.71M |
Valuation Ratios
The trailing PE ratio is 17.00.
| PE Ratio | 17.00 |
| Forward PE | n/a |
| PS Ratio | 0.55 |
| PB Ratio | 0.99 |
| P/TBV Ratio | 1.01 |
| P/FCF Ratio | 43.73 |
| P/OCF Ratio | 16.61 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 12.39, with an EV/FCF ratio of 52.62.
| EV / Earnings | 20.47 |
| EV / Sales | 0.66 |
| EV / EBITDA | 12.39 |
| EV / EBIT | 18.86 |
| EV / FCF | 52.62 |
Financial Position
The company has a current ratio of 1.09, with a Debt / Equity ratio of 0.31.
| Current Ratio | 1.09 |
| Quick Ratio | 0.63 |
| Debt / Equity | 0.31 |
| Debt / EBITDA | 3.23 |
| Debt / FCF | 13.72 |
| Interest Coverage | 6.81 |
Financial Efficiency
Return on equity (ROE) is 6.09% and return on invested capital (ROIC) is 4.87%.
| Return on Equity (ROE) | 6.09% |
| Return on Assets (ROA) | 2.22% |
| Return on Invested Capital (ROIC) | 4.87% |
| Return on Capital Employed (ROCE) | 5.14% |
| Weighted Average Cost of Capital (WACC) | 5.85% |
| Revenue Per Employee | 707.65M |
| Profits Per Employee | 22.97M |
| Employee Count | 248 |
| Asset Turnover | 1.01 |
| Inventory Turnover | 3.39 |
Taxes
In the past 12 months, Kukje Pharma has paid 738.54 million in taxes.
| Income Tax | 738.54M |
| Effective Tax Rate | 11.46% |
Stock Price Statistics
The stock price has increased by +1.37% in the last 52 weeks. The beta is 0.47, so Kukje Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.47 |
| 52-Week Price Change | +1.37% |
| 50-Day Moving Average | 4,844.20 |
| 200-Day Moving Average | 4,595.80 |
| Relative Strength Index (RSI) | 45.50 |
| Average Volume (20 Days) | 198,303 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Kukje Pharma had revenue of KRW 175.50 billion and earned 5.70 billion in profits. Earnings per share was 280.00.
| Revenue | 175.50B |
| Gross Profit | 93.64B |
| Operating Income | 6.18B |
| Pretax Income | 6.44B |
| Net Income | 5.70B |
| EBITDA | 9.41B |
| EBIT | 6.18B |
| Earnings Per Share (EPS) | 280.00 |
Balance Sheet
The company has 10.72 billion in cash and 30.40 billion in debt, with a net cash position of -19.68 billion or -966.50 per share.
| Cash & Cash Equivalents | 10.72B |
| Total Debt | 30.40B |
| Net Cash | -19.68B |
| Net Cash Per Share | -966.50 |
| Equity (Book Value) | 97.70B |
| Book Value Per Share | 4,810.44 |
| Working Capital | 5.36B |
Cash Flow
In the last 12 months, operating cash flow was 5.84 billion and capital expenditures -3.62 billion, giving a free cash flow of 2.22 billion.
| Operating Cash Flow | 5.84B |
| Capital Expenditures | -3.62B |
| Depreciation & Amortization | 3.23B |
| Net Borrowing | 816.01M |
| Free Cash Flow | 2.22B |
| FCF Per Share | 108.84 |
Margins
Gross margin is 53.36%, with operating and profit margins of 3.52% and 3.25%.
| Gross Margin | 53.36% |
| Operating Margin | 3.52% |
| Pretax Margin | 3.67% |
| Profit Margin | 3.25% |
| EBITDA Margin | 5.36% |
| EBIT Margin | 3.52% |
| FCF Margin | 1.26% |
Dividends & Yields
This stock pays an annual dividend of 30.00, which amounts to a dividend yield of 0.63%.
| Dividend Per Share | 30.00 |
| Dividend Yield | 0.63% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 5 |
| Payout Ratio | 10.72% |
| Buyback Yield | -0.08% |
| Shareholder Yield | 0.55% |
| Earnings Yield | 5.88% |
| FCF Yield | 2.29% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on March 17, 2023. It was a forward split with a ratio of 1.05.
| Last Split Date | Mar 17, 2023 |
| Split Type | Forward |
| Split Ratio | 1.05 |
Scores
Kukje Pharma has an Altman Z-Score of 1.87 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.87 |
| Piotroski F-Score | 6 |